A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

Condition:   PARP Inhibitor for Esophageal Squamous Cell Carcinoma Intervention:   Drug: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm)) Sponsor:   Chongqing University Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials